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Formalin-fixed, paraffin-embedded (FFPE), biobanked tissue samples offer
an invaluable resource for clinical and biomarker research. Here, we devel-
oped a pressure cycling technology (PCT)-SWATH mass spectrometry
workflow to analyze FFPE tissue proteomes and applied it to the stratifica-
tion of prostate cancer (PCa) and diffuse large B-cell lymphoma (DLBCL)
samples. We show that the proteome patterns of FFPE PCa tissue samples
and their analogous fresh-frozen (FF) counterparts have a high degree of
similarity and we confirmed multiple proteins consistently regulated in PCa
tissues in an independent sample cohort. We further demonstrate temporal
stability of proteome patterns from FFPE samples that were stored
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between 1 and 15 years in a biobank and show a high degree of the pro-
teome pattern similarity between two types of histological regions in small
FFPE samples, that is, punched tissue biopsies and thin tissue sections of
micrometer thickness, despite the existence of a certain degree of biological
variations. Applying the method to two independent DLBCL cohorts, we
identified myeloperoxidase, a peroxidase enzyme, as a novel prognostic
marker. In summary, this study presents a robust proteomic method to
analyze bulk and biopsy FFPE tissues and reports the first systematic com-
parison of proteome maps generated from FFPE and FF samples. Our
data demonstrate the practicality and superiority of FFPE over FF sam-
ples for proteome in biomarker discovery. Promising biomarker candidates
for PCa and DLBCL have been discovered.
1. Introduction
Quantitative molecular profiling of phenotypically
well-annotated clinical sample cohorts using genomic,
transcriptomic, or metabolomic techniques, followed
by the statistical association of molecular and pheno-
typic data has been a powerful approach for the devel-
opment of biomarkers, guiding classification,
stratification, and therapy, particularly with regard to
cancer patients (Ritchie et al., 2015; Sawyers, 2008).
With the increasing robustness, accuracy, and through-
put of molecular profiling techniques, the need for
large, well-annotated sample cohorts has been accentu-
ated over the last few years.
The history of FFPE samples dates back to 1893
(Blum, 1893). Most human tissue specimens archived
in hospitals for diagnostic purposes are FFPE blocks
which have been shown to be stable over time and are
usually associated with rich clinical and phenotypic
data, including histology, diagnosis, treatment history
and response, and outcome. For fresh or rapidly fro-
zen tissue samples, such meta data are less frequently
available and concerns about molecular stability over
time have been raised (Chu et al., 2002; Shabihkhani
et al., 2014). FFPE samples have been globally used
for DNA, RNA, protein, and morphological measure-
ments, and preanalytical factors affecting each type of
measurement have been identified (Bass et al., 2014).
Besides, various techniques and evaluation studies
have been reported for genomic (Martelotto et al.,
2017; Van Allen et al., 2014), transcriptomic (von Ahl-
fen et al., 2007; Li et al., 2014), proteomic and protein
(Giusti and Lucacchini, 2013; Gustafsson et al., 2015;
Hood et al., 2005; Ostasiewicz et al., 2010) from FFPE
samples.
The preparation of FFPE samples depends on the
exposure of the tissue to a range of chemical reactions
and conditions. During fixation, formaldehyde reacts
with proteins or peptides to form unstable methylol
adducts (specified by a C–O bond) which further par-
tially dehydrate to yield active intermediate Schiff
bases. These intermediate products subsequently react
with basic and aromatic amino acids to form stable
and irreversible methylene bridge cross-links (specified
by a C–N bond) (Giusti and Lucacchini, 2013; Shi
et al., 2013), thus modifying the sample proteins. Pro-
tein analysis of FFPE tissues using antibodies started
in 1991 with the development of the heat-induced anti-
gen retrieval (HIAR) technique for immunohistochem-
istry (IHC) (Shi et al., 1991). HIAR is based on the
notion that heating may unmask epitopes by hydroly-
sis of methylene cross-links, thus enhancing immunore-
activity. Consequently, the measurement of specific
proteins by HIAR has become widely used for diag-
nostic and prognostic biomarker testing, particularly
in cancers (Shi et al., 2011). To extend the analysis of
proteins to a proteomic scale, a number of different
methods have been used to retrieve proteins from
FFPE samples for mass spectrometric analysis
(Broeckx et al., 2016; Fowler et al., 2014; Fu et al.,
2013; Jain et al., 2012; Jiang et al., 2007; Ostasiewicz
et al., 2010; Shen et al., 2015; Wakabayashi et al.,
2014). They include high pressure (Fu et al., 2013) or
pressure cycling technology (Fowler et al., 2014), and
the available methods have been recently reviewed
(Giusti and Lucacchini, 2013; Gustafsson et al., 2015).
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These studies have shown that FFPE samples can, in
principle, be analyzed by mass spectrometry-based
proteomic methods. However, the proteome maps of
FFPE tissues and their analogue FF tissues from clini-
cal cohorts and their respective stability over time have
not been rigorously assessed. The concern remains that
FFPE samples may harbor greater variation in protein
quality than FF samples due to formalin-induced
chemical modifications (Gaffney et al., 2018).
Multiple factors might have contributed to these
limitations. First, the generation of clinically meaning-
ful results requires the consistent analysis of sizable
sample cohorts. Second, reproducible sample prepara-
tion and mass spectrometric analysis that are essential
for clinical studies have been difficult to achieve. Few
if any published studies on FFPE proteomic analyses
have ever attempted to repeat analysis on clinical spec-
imens of a cohort due to the complexity and high cost
of the adopted proteomics techniques (Holfeld et al.,
2018; Hughes et al., 2016; Quesada-Calvo et al., 2015).
Third, the ability to analyze a histological region of
small FFPE samples remains challenging. Most pub-
lished studies analyzed tissue micrometer sections with
each tissue containing multiple histological types
(Drendel et al., 2017; Holfeld et al., 2018; Piehowski
et al., 2018). Laser capture microdissection has been
used to analyze multiple regions of a tissue section;
however, experimental complexities preclude applica-
tion to large-scale analysis. Targeted needle punches
from a FFPE tissue block represent a reasonable com-
promise; however, efficient extraction of proteins from
such a small needle biopsy and further proteolytic
digestion of the proteins into peptides for mass spec-
trometric analysis has not been reported yet. Finally,
although methods are available to analyze proteins
from human and animal FFPE samples (Ostasiewicz
et al., 2010), concerns remain whether the thus
extracted proteins reliably reflect their actual abun-
dance pattern in the fresh-frozen counterpart and, ulti-
mately, fresh samples (Gaffney et al., 2018).
To effectively and reproducibly disrupt the FFPE
tissue punches, PCT has been adopted to accelerate
the protein extraction efficiency for breaking down
the tissue structure by making use of alteration
between high and low pressures, and to speed up the
enzymatic digestion because the enhanced enzymatic
activity under this circumstance (Guo et al., 2015;
Shao et al., 2015, 2016). In this study, we revisited
and optimized the acidic and alkaline hydrolysis pro-
cedures developed in 1947 (Fraenkelconrat et al.,
1947) which are compatible with a detergent-free pro-
tocol to recover proteins from small
(0.5 9 0.5 9 3 mm) FFPE tissue punches in a form
that is directly compatible with in-solution digestion
within an hour. The thus treated tissue samples can
be directly processed by the PCT method to generate
mass spectrometry-ready peptide samples within a few
hours. We further investigated whether the thus
acquired FFPE proteome map is comparable to its
counterpart FF proteome map in prostate tissue sam-
ples by applying this workflow to identify promising
diagnostic protein biomarkers for PCa patients. We
found that the two types of patterns were highly simi-
lar and identified strongly overlapping sets of proteins
that showed different levels of expression in benign
and tumor tissue. Subsequently, the effect of factors
such as storage time and FFPE tissue forms to the
proteome was further evaluated. There is no signifi-
cant difference among FFPE proteome patterns with
different storage time, while tissue sections were sepa-
rated from punched tissue biopsies based on principal
component analysis (PCA).
Further, a panel of 12 proteins showing great poten-
tial for PCa diagnosis was characterized in an indepen-
dent Chinese prostate cohort and was validated in the
Swiss cohort in this study as well as in other two
recently reported PCa studies (Iglesias-Gato et al.,
2016; Latonen et al., 2018). As a second application,
the FFPE PCT-SWATH workflow was applied to
identify prognostic biomarkers for diffuse large B-cell
lymphoma (DLBCL) patients, employing the relevant
archived FFPE tissues. Myeloperoxidase (MPO) was
identified as a promising novel prognostic candidate
for DLBCL.
2. Materials and methods
2.1. Prostate tissue Specimens
Both FF and FFPE tissues from Zurich (the PCF
cohort) were kindly provided by PJW in the form of
punches from the Department of Pathology and
Molecular Pathology, University Hospital Zurich.
Samples were collected within the ProCOC study
(Umbehr et al., 2008), a prospective ongoing biobank-
ing trial led by PJW and CP. The size of a single FF
tissue biopsy was about 1 mm3 (diameter 1 mm; length
1–2 mm; wet weight was about 800 lg). The size of a
single FFPE punch is about 0.5 9 0.5 9 3 mm, and
the dry mass weighed about 300 lg including wax
(Fig. 1A). The Cantonal Ethics Committee Zurich
(KEK-ZH) has approved all procedures involving
human material, and each PCa patient has signed an
informed consent form (KEK-ZH-No. 2008-0040).
Patients were followed on a regular basis, every
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3 months during the first year and afterward at least
annually or on an individual basis depending on the
disease course. A PSA value of 0.1 ngmL1 or higher
was defined as biochemical recurrence (al).
Prostate FFPE samples from China (PCZA cohort)
were procured in the Second Affiliated Hospital of
College of Medicine, Zhejiang University, with
approval from the hospital ethics committee. The size
of a single FFPE punch of PCZA cohort is about
1 9 1 9 5 mm, and the dry mass weighed about 1–
1.5 mg including wax. Three punches were collected
from each tissue sample.
Prostate FFPE samples from China (PCZC cohort)
were procured in the First Affiliated Hospital of Col-
lege of Medicine, Zhejiang University, with approval
from the hospital ethics committee. The cohort con-
tained two forms of archived FFPE samples that are
micrometer sections (5 lm thickness) and tissue biopsy
punches (1 9 1 9 0.5 mm). Three biological replicates
were collected for each sample. The samples have been
archived for a variety of time spans of 1, 5, 10 to
15 years.
The PCa study here was also approved by ethics
committee of Westlake University.
Fig. 1. Formalin-fixed, paraffin-embedded PCT-SWATH protocol and performance. (A) Prostate FFPE tissue in a punch. (B) Acid, base, and
heat treatment to reverse cross-links. (C) Schematic protocol of FFPE PCT-SWATH. (D) Peptide yield per milligram FFPE tissue with
different Tris/HCl (pH 10.0) boiling time. (E) Number of peptides identified by the peptides prepared with different Tris/HCl boiling time. (F)
Yield of peptides from 48 prostate tissue samples.
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All the study methodologies conformed to the stan-
dards set by the Declaration of Helsinki.
2.2. Lymphoma specimens
Formalin-fixed, paraffin-embedded tissues from 41
patients with primary central nervous system lym-
phomas (PCNSL), extracerebral DLBCL (eDLBCL),
and intravascular lymphoma (IVL) who had signed
an informed consent and had been treated at the
University Hospital Zurich between 2005 and 2014
were collected. Studies were approved by the Institu-
tional Review Board (KEK-StV-Nr.19/08). FFPE
punches (each FFPE punch measuring about
0.5 9 0.6 9 3 mm) were produced in the Department
of Pathology, University Hospital Zurich. Two to
three punches were collected from each tissue sample.
An independent cohort of 52 DLBCL patients was
procured from the First Affiliated Hospital of College
of Medicine, Zhejiang University, with approval from
the hospital ethics committee. Five sections with thick-
ness of 10 lm were collected for each tissue sample.
The DLBCL study here was also approved by ethics
committee of Westlake University.
2.3. De-paraffinization, rehydration, and
hydrolysis of FFPE tissues
The FFPE tissue was put into a 2-mL safe-lock
Eppendorf tube and was firstly subjected to the dewax-
ing step by incubation with 1 mL of heptane, and then
gently vortexed at 800 r.p.m. for 10 min at 30 °C on a
thermomixer (cap closed). The dewaxing was repeated
once. The sample was then subjected to gradient rehy-
dration steps and gently vortexed at 800 r.p.m. with
1 mL 100%, 90%, 75% of ethanol, respectively, each
time at 25 °C for 5 min (cap closed). At the third step,
each tissue sample was further incubated with 200 lL
0.1% formic acid (FA) for 30 min at 30 °C for rehy-
dration and the acidic hydrolysis, by gently vortexing
at 800 r.p.m. (cap closed). Lastly, the tissue sample
was transferred into a PCT-MicroTube (Pressure Bio-
sciences Inc., South Easton, MA, USA), briefly
washed with 100 lL of 0.1 M Tris/HCl (pH 10.0,
freshly prepared) to remove remaining FA, and was
then incubated with 15 lL of fresh 0.1 M Tris/HCl
(pH 10.0), boiled at 95 °C for 30 min, by gently vor-
texing at 600 r.p.m. to undergo a heat and base
induced hydrolysis (cap closed).
Once hydrolysis was finished, the PCT-MicroTube
with FFPE tissue bathed in Tris/HCl (pH 10.0) was
immediately placed on ice for cooling, then 25 lL of
lysis buffer (6 M Urea, 2 M thiourea, 5 mM Na2EDTA
in 100 mM ammonium bicarbonate, pH 8.5) was added
to the solution (final pH around 8.8). Both the tissue
sample and supernatant from this step were kept for
subsequent PCT-assisted tissue lysis and protein diges-
tion.
2.4. PCT-assisted tissue lysis, protein extraction,
and protein digestion
Briefly, the FFPE tissue sample was lysed with lysis
buffer in a barocycler NEP2320-45k (Pressure BioS-
ciences Inc.) at the PCT scheme of 30 s high pressure
at 45 kpsi plus 10 s ambient pressure, oscillating for
90 cycles at 30 °C. Then, the extracted protein solu-
tion was reduced and alkylated by incubating with
10 mM tris(2-carboxyethyl)phosphine (TCEP) and
20 mM iodoacetamide (IAA) at 25 °C for 30 min, in
darkness, by gently vortexing at 800 r.p.m. in a ther-
momixer. Afterward, proteins were firstly digested by
Lys-C (Wako, VWR, VA, USA; enzyme-to-substrate
ratio, 1 : 40) in the barocycler using the PCT scheme
of 50 s high pressure at 20 kpsi plus 10 s ambient
pressure, oscillating for 45 cycles at 30 °C. Then, a
subsequent tryptic digestion step followed (Progemga,
Madison, WI, USA; enzyme-to-substrate ratio, 1 : 20)
using the PCT scheme of 50 s high pressure at
20 kpsi plus 10 s ambient pressure, oscillating for 90
cycles at 30 °C. Peptide samples were then acidified
by trifluoroacetic acid (TFA) prior to C18 desalting.
The FF tissue samples were processed as described
previously (Guo et al., 2015) with only the change of
replacing the normal microcaps with micropestles
(Shao et al., 2016).
2.5. SWATH mass spectrometry
All samples were spiked with iRT peptides (Biognosy-
sis; Escher et al., 2012). 0.6 lg of cleaned peptides
(0.3 lg per injection, in technical duplicates) was ana-
lyzed by SWATH-MS on a 5600 (PCF cohort) or 6600
TripleTOF mass spectrometer (WLYM cohort) con-
nected to a 1D+ Nano liquid chromatography (LC)
system (Eksigent, Dublin, CA, USA; Guo et al., 2015,
2018). The LC gradient was mixed with buffer A (2%
acetonitrile and 0.1% FA in HPLC water) and buffer
B (2% water and 0.1% FA in acetonitrile). The ana-
lytical column was home-made (75 lm 9 20 cm) using
a fused silica PicoTip emitter (New Objective,
Woburn, MA, USA) and 3 lm 200 A Magic C18 AQ
resin (Michrom BioResources, Auburn, CA, USA).
Peptide samples were separated with a linear gradient
of 2–35% buffer B over 30 min (the PCF cohort) or
60 min (the WLYM cohort) LC gradient time at a
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flow rate of 0.3 lLmin1. Ion accumulation time for
MS1 was 50 and 40 ms for MS2 acquisition, respec-
tively. SWATH window schemes were optimized to 48
variable windows. The instrument was operated in
high-sensitivity mode.
The PCZA, PCZC, and ZLYM cohorts from China
were analyzed in a TripleTOF 5600+ coupled to an
Eksigent Nano LC 415 (with a 1–10 lLmin1 flow
module to switch the LC from nanoflow to microflow).
Composition of mobile phase was the same as that in
Zurich laboratory. Eksigent Analytical column
(0.3 9 150 mm C18 ChromXP 3 lm) and trap column
(0.3 9 10 mm, C18 ChromXP 5 lm) were used for
chromatographic separation. Two microgram of peptide
samples was separated with a linear gradient of 3–25%
buffer B over 120 min (the PCZA cohort) or 90 min
(the PCZC and ZLYM cohort) LC gradient time at a
flow rate of 5 lLmin1. SWATH acquisition method
was the same as the method at Zurich laboratory except
a slightly longer MS2 accumulation time of 60 ms.
2.6. SWATH data analysis
We built a SWATH assay library after analyzing
unfractionated prostate tissue digests prepared by the
PCT method in data-dependent acquisition (DDA)
mode on a 5600 TripleTOF mass spectrometer over a
gradient of 2 h as previously described (R€ost et al.,
2014). SWATH data were first analyzed using OPEN-
SWATH (openms 1.10.0; R€ost et al., 2014) as described
(Guo et al., 2015). Retention time extraction window
was 300 s, and m/z extraction was performed with
0.05 Da tolerance. Retention time was calibrated using
iRT peptides. The sample for each peptide precursor
that was identified by OPENSWATH with the lowest
m_score was treated as the reference sample for each
peptide precursor and was used as input for DIA-ex-
pert analysis (https://github.com/tiannanguo/dia-expe
rt). Briefly, all b and y fragments for each identified
peptide precursor in the Spectrast library were re-ana-
lyzed using OpenSwathChromatogramExtractor
(openms 1.10.0) for all samples. A reference sample
was selected for each peptide precursor based on the
m_score from OpenSWATH analysis described above.
For reference sample, peptide fragments forming good
peak shape were refined in all samples. Peptide precur-
sors with less than four good peak-forming fragments
were excluded. Each sample, except the reference sam-
ple, in the sample set was pairwise compared with the
reference sample at fragment level, and the median
proportion of all fragments was used for quantification
of the peptide precursor in a sample. The MS2-level
total ion chromatogram for each SWATH window
was used to normalize the peak group area. Peptide
precursors that were quantified in technical duplicates
with a fold-change value equal or higher than two
were excluded. The most reliable peptide precursor
from a protein, that is, best flier peptide, was selected
to represent the abundance of a protein because we
found that inclusion of poorly responded peptide pre-
cursors negatively influenced to the quantitative accu-
racy, and that for high abundance proteins with
multiple peptides, the best flier peptide selected by the
DIA-expert was representative and exhibited the low-
est number of missing values. All codes are provided
in Github.
2.7. Tissue microarray and
immunohistochemistry
The Ethics Committee of the Kanton St. Gallen,
Switzerland, approved all procedures involving human
materials used in this St. Gallen tissue microarray
(TMA), and each patient signed an informed consent.
The construction of TMA and IHC procedures have
been was described previously (Guo et al., 2018). The
POSTN antibody was from Abcam (Cambridge, MA,
USA; ab14041). The MPO antibody was from
NeoMarkers/Lab Vision Corporation (Thermo Fisher
Scientific, Cheshire, UK; RB-373-A1).
2.8. Statistical analysis
All plots were produced with R Violin plots were made
using the R package vioplot. Pearson’s correlation was
used to compute the correlation coefficient. Two-tailed
paired Student’s t-test was employed to compute prob-
ability in Volcano plots. Kaplan–Meier estimators
were used for RFS analysis. Point-wise 95% confi-
dence bands were computed for the whole range of
time values. Differences between survival estimates
were evaluated by the log-rank test.
3. Results
3.1. Establishment of a FFPE PCT-SWATH
workflow
We integrated a workflow for the generation of pro-
teome map from FFPE tissue samples in a robust and
high-throughput manner. In addition, we showed that
the proteome map derived from FFPE samples corre-
late well with corresponding maps generated from
their analogous FF samples and that the same biomar-
ker panel can be identified from both sample types,
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even if the samples have been stored for 4–8 years in
their respective format. The de-cross-linking of FFPE
tissue is based on acidic and alkaline hydrolysis which
was developed in 1947 (Fraenkelconrat et al., 1947;
Kamath et al., 1985) but has not been reported in pro-
teomics research applications yet. Here, we integrated
the classical de-cross-linking method with PCT-assisted
protein extraction and digestion, and SWATH-MS
(Gillet et al., 2012; Guo et al., 2015) method to estab-
lish a detergent-free FFPE PCT-SWATH workflow.
To achieve the desired overall performance profile,
protocols for the chemical extraction of proteins from
FFPE tissue, LC, SWATH-MS, and data analysis were
optimized and integrated.
3.1.1. Chemical extraction of proteins from FFPE
tissue punches
A detergent-free and fast hydrolysis protocol for prepar-
ing MS-ready peptides from FFPE tissue punch samples
mimicking needle biopsies (width < 1 mm, length ~ 2–
3 mm; dry mass weight about 300–400 lg; Fig. 1A) was
optimized. The method consists of (a) an acidic hydroly-
sis step (0.1% formic acid) to achieve C–O hydrolysis of
protein methylol products (Fig. 1B), (b) a step of heat
and base induced hydrolysis to reverse the C–N methy-
lene cross-links (Fig. 1B,C) and (c) extraction and diges-
tion of proteins from the thus pretreated punches by
PCT (Fig. 1C). The FFPE tissue biopsies used for the
protocol establishment were from a sample pool of 48
replicate tissue biopsies extracted from a resected pros-
tate of the ProCOC cohort (Umbehr et al., 2008; Wett-
stein et al., 2017a,b). We optimized the acidic and
alkaline hydrolysis steps by varying the respective treat-
ment times. Acidic hydrolysis was achieved concurrent
with the complete rehydration of FFPE tissue punches
by replacing water with 0.1% formic acid. Preliminary
UV spectroscopy results showed that the release of
methylol groups began saturated in 30 min. As to the
alkaline hydrolysis, the effects of the different tested
conditions were evaluated by determining the peptide
yield as well as the number and type of peptides and pro-
teins identified from each sample by SWATH-MS
(Fig. 1D,E). At this step, 30-min boiling of the FFPE
punch with 0.1 M Tris/HCl (pH 10.0) at 95 °C led to the
highest peptide yield with the greatest number of identi-
fied peptides. As shown in Fig. 1F, we generated on
average of about 60 lg peptide mass per milligram
FFPE tissue sample (dry mass with wax). The yield was
comparable to our previous investigations of fresh-fro-
zen tissues (wet tissue), of which the mean peptide yield
is about 50 lg (Guo et al., 2015, 2018; Shao et al., 2015,
2016; Zhu et al., 2019).
3.1.2. Optimization of LC and SWATH-MS
We assessed the combined effects of LC gradient
length (30, 45, and 60 min) and SWATH window con-
figuration (eight configurations, ranging from 20 to 93
variable windows) on sample throughput, proteome
depth, and reproducibility. Each window scheme
assessed was based on equal segmentation of precursor
ion signals over the entire mass range. The peptides
used for the optimization of LC and SWATH settings
were randomly selected from nine peptide samples
obtained from FFPE tissues processed with the 30-min
alkaline hydrolysis protocol described above (Fig. 1E).
Altogether, we compared 24 LC-SWATH conditions
in duplicate (Fig. S1a–c). The results showed that 48
variable SWATH windows achieved the highest num-
ber of peptide and protein identifications. We observed
a trade-off between the gradient length and proteome
coverage. The 30-min LC gradient resulted in a 19%
lower number of peptide identifications and 8% fewer
protein identifications, compared to the 60 min LC
gradient (Fig. S1b,c).
3.2. Comparison of FFPE and FF tissue proteome
maps
To investigate whether the obtained FFPE proteome
maps were comparable to their FF counterparts, we
performed proteomic analyses of corresponding FFPE
and FF counterpart tissue samples of 24 PCa patients
with radical prostatectomy from the ProCOC cohort
(Umbehr et al., 2008; Wettstein et al., 2017a,b). Sec-
tions of tissue samples from the same resected pros-
tates have been stored for 4–8 years in the form of
FFPE or FF, respectively, prior to proteomic analysis
(Fig. 2A, Table S1). Only the index tumor with the
highest Gleason score and the largest diameter was
selected for analysis. For nontumorous tissue, benign
prostatic tissue with minimal stromal component was
chosen.
With respect to FFPE tissues, three replicate
punches were processed via the FFPE PCT-SWATH
workflow for each sample and combined for PCT-
SWATH analysis. The size of each tissue biopsy was
around 0.5 9 0.5 9 3 mm, weighing approximately
300 lg including wax. In total, approximately 900 lg
of dry mass weight was available per FFPE sample.
For the FF cohort, one tissue punch of approximately
1 mm3 size and wet weight of about 800 lg per sample
was processed by PCT-SWATH. Altogether, 48 FFPE
tissue samples (benign and tumor) were processed into
peptide samples that were analyzed by SWATH-MS in
technical duplicates. Figure 1F shows that the samples
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produced on average about 60 lg injection-ready pep-
tide mass per milligram of tissue sample. The yield is
consistent with previous reports for FF tissues (Guo
et al., 2015; Shao et al., 2015, 2016). The CV values of
peptide yield were 49% and 65% for benign and
tumorous tissues, respectively, slightly higher than the
corresponding figures reported previously for FF kid-
ney tissues (about 41% for biological variations; Guo
et al., 2015). The difference in peptide yield is likely
caused by inaccurate estimation of FFPE tissue weight
due to variable wax content and the heterogeneity of
human prostate tissues.
The setting of 30-min LC integrated with 48 variable
SWATH windows was adopted for protein measure-
ment to compare FFPE and FF tissue proteome maps
in this study. Two technical replicates for each tissue
digest were analyzed using SWATH-MS, referred to in
the following as PCF dataset. The resulting SWATH-
MS data from all 96 FFPE and FF samples were com-
pared by their total ion current and the number and
type of peptides as well as proteins that could be iden-
tified and quantified.
We first compared the raw ion intensity signals over
chromatographic time (total ion chromatogram, TIC)
at both the MS1 and MS2 levels. We found that the
TIC, normalized for total injected peptide mass, was
on average 15% higher for FF than for FFPE samples
(Fig. S2). The observed small discrepancy of normal-
ized MS1 intensity values is likely due to incomplete
acidic and alkaline hydrolysis of cross-links, resulting
in the generation of partially hydrolyzed methylene
bridges, which contribute to the absorbance in the
range from 260 to 280 nm on the spectroscopy. The
modification by formalin could also lead to ion sup-
pression. The root cause for lower specific TIC was
not further investigated because the effect was minor
and the contour of the TIC for FF and FFPE samples
were very similar, suggesting that comparable peptide
populations were generated from both sample types
(Fig. S2).
Next, we used the SWATH-MS fragment ion maps
to compare the number and type of peptides and pro-
teins that could be identified from FF and FFPE sam-
ples, and their respective quantities. We used the
OPENSWATH (R€ost et al., 2014) software tool and a
spectral library built from prostate tissue, consisting of
70 981 peptide precursors from 6686 SwissProt pro-
teins, to search the acquired fragment ion maps. Alto-
gether, we obtained quantitative data for 3030
SwissProt proteins inferred from 18 129 proteotypic
peptides. The median technical CV analyses were
14.9% and 17.5% for FF and FFPE samples, respec-
tively. Overall median CV was 16.2% (Fig. 2B,
Fig. S3). We further compared the overall proteomic
variation for different tissue types including benign
and tumorous FFPE versus FF samples and found no
significant discrepancy (Fig. S4). We then compared
the peptide precursors and proteins detected in each
paired FFPE and FF sample (Fig. S5) and found that
peptides as well as proteins were consistently quanti-
fied in both tissue types with relatively high Pearson
correlation. The overall correlation between FFPE and
FF samples reached a Pearson correlation of 0.91
(Fig. 2C) with a median normalization of the data
based on protein abundance. With unsupervised clus-
tering, the proteome map from FFPE samples was
mixed with FF samples (Fig. S6a), further supporting
the notion that the data generated from FFPE samples
are comparable with those of FF samples. Curated
MS signals by the viewer function of the DIA-expert
software for a representative peptide which was quan-
tified across all 224 SWATH runs are shown in
Fig. 2. Comparison of FF and FFPE tissues in a patient cohort. (A) Benign and tumorous samples were punched from prostate tissue stored
since resection as FF and FFPE. The hematoxylin and eosin staining of FF and FFPE tissue from Patient No. 2 in the ProCOC cohort is
shown here. AL, anterior left; AR, anterior right; PL, posterior left; PR, posterior right. (B) Overall technical CV of FFPE and FF samples at
peptide level. (C) Comparison of median protein abundance in FF (x-axis) versus FFPE (y-axis) samples. Each dot denotes one protein
identified in this sample cohort.
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Fig. S6b. We further compared the raw signals, quan-
tity of peptide precursors, and proteins in samples
stored for different periods of time and observed no
significant impact of storage time (Fig. S7).
Overall, the data show that a highly consistent and
significant fraction of the whole proteome, consisting
of 3030 SwissProt proteins, could be reproducibly
identified from equivalent FF and FFPE samples, even
after 8 years storage. Furthermore, the quantitative
information generated from matched FFPE and FF
sample pairs were comparable.
3.3. Systematic evaluation of the effect of FFPE
tissue storage format and duration on proteome
maps
We next evaluated the robustness of proteome maps
obtained from FFPE tissue stored in different formats
and for different periods of time. We procured FFPE
tissue samples from three benign prostatic hyperplasia
(BPH) patients from China (termed as ‘PCZC’ cohort).
For each patient, we collected both tissue sections
(5 lm thickness) and punched tissue biopsies
(1 9 1 9 0.5 mm). For each sample format, we ana-
lyzed three biological replicates. The samples had been
archived for different periods of time, specifically for
1, 5, 10, and 15 years, respectively. Altogether, 72 tis-
sue samples were processed, and 72 SWATH files were
acquired with a 90-min LC gradient in a TripleTOF
5600+ mass spectrometer coupled to an Eksigent
microflow system.
We reproducibly quantified 3040 SwissProt proteins
in both tissue punches and sections in this dataset. By
comparing the protein abundance distribution of these
common proteins, we found that the proteome maps
of the two FFPE formats showed a high degree of
similarity, with a Pearson correlation coefficient of
0.95 (Fig. 3A). The mean Pearson correlation coeffi-
cient of all 72 samples among their own biological
replicates was 0.858, showing that the samples were of
high similarity at the whole proteome level (Fig. 3B).
Unsupervised cluster analysis of all 3040 proteins also
showed consistent distribution of protein abundance
among all 72 samples (Fig. 3C). We further grouped
the 72 samples into eight groups according to sample
format and storage time and investigated the biological
variation of nine samples (three patients, each with
three biological replicates) in each group. The average
CV slightly varied between tissue micrometer sections
and punches across the time span of 15 years
(Fig. 3D). Further, tissue micrometer sections were
found to be different from punches (Fig. 3E), probably
due to that fact that tissue micrometer sections cover
more diverse tissue regions and therefore contain
higher degree of the spatial heterogeneity (Guo et al.,
2018). However, these differences only affected a small
portion of proteins. The duration of FFPE storage did
not impact on our proteomic measurement, further
reinforcing the stability of FFPE proteome and the
robustness of our protocol (Fig. 3F).
3.4. Identification of a subset of proteins with
comparable abundance patterns in prostate FFPE
and FF punches
Next, we asked whether proteins distinguishing benign
and tumorous prostate tissue could be consistently
detected in both FFPE and FF samples. We observed
differential expression of multiple proteins between
benign and tumorous tissues in both FFPE and FF
samples in the PCF cohort (Fig. 4A,B).
We first determined proteins that were significantly
differentially regulated between the FF tumor and
benign samples. We computed the median fold-change
of tumor-to-benign tissue samples and the P values for
each protein in the 24 patients for FF tissue samples.
By setting a fold-change (FC) cutoff of 2 and a P
value cutoff at 0.05, only three proteins were signifi-
cantly upregulated in tumor compared to benign tis-
sue. These are Q9BUD6 (SPON2), O95994 (AGR2),
and Q15063 (POSTN), as is shown in Fig. 4B.
Remarkably, these three proteins are all promising
biomarker candidates. SPON2 is a secreted extracellu-
lar matrix protein. In a previous study, it was detected
as an abundant protein in serum samples of 286 PCa
patients compared to 68 healthy controls (Lucarelli
et al., 2013). In particular, it was found with signifi-
cantly higher expression levels in PCa patients with a
Gleason score of 7–8 and in PCa patients with metas-
tases (Lucarelli et al., 2013; Qian et al., 2012). AGR2
is a secreted adenocarcinoma-associated antigen. The
mRNA level of AGR2 was found higher in cancerous
tissue in 42 paired PCa samples, but it was not associ-
ated with survival in the cohort (Kristiansen et al.,
2005). In addition, the protein expression level of
AGR2 was found increased in cancerous tissue in 31
out of 58 PCa cases by IHC immunolabeling (Kris-
tiansen et al., 2005), a result that was consistent with
two independent cohorts (Bu et al., 2011). In this
study, the expression of AGR2 was found to be about
four times higher in tumor compared to benign tissue
and, remarkably, its abundance level positively corre-
lated with survival (P = 0.008), as is shown in Fig. 4C.
POSTN is an extracellular matrix protein involved in
cell development and adhesion. We have previously
reported its upregulation in high grade and advanced
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stage PCa patients (Tischler et al., 2010), which is con-
sistent with an independent report of its positive prog-
nostic value in PCa (Nuzzo et al., 2012), and with a
study of its positive correlation with the aggressiveness
of PCa (Tian et al., 2015). In this study, POSTN was
found to be expressed 2–4 times higher in malignant
compared to corresponding benign tissue samples, and
its abundance level positively correlated with survival
(P = 0.009), as shown in Fig. 4D.
We then analyzed the SWATH data acquired for
FFPE samples in the same way and found 24 proteins
with significantly different abundance between tumor
and benign groups. The results from the FFPE cohort
recapitulated the pattern of the three proteins with
increased tumor abundance identified in the FF
cohort. The consistency of the detected changes for
these proteins is remarkable given the intratumor
heterogeneity, expected differences between the FFPE
Fig. 3. Evaluation of FFPE tissue storage forms and duration. (A) Pearson correlation of protein abundance between FFPE micrometer
sections and punches. (B) Average Pearson correlation coefficient of all 72 samples among three biological replicates. The
‘pairwise.complete.obs’ method was employed to calculate the COR value to avoid the influence of NA. (C) The protein abundance
distribution of all 3040 SwissProt proteins across all 72 samples with different tissue types and storage time. (D) CV plots for each sample
type (section/punch) with different storage time (1, 5, 10, and 15 years). (E) PCA of the effect of tissue types. (F) PCA of the effect of
storage time.
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Fig. 4. Comparison of regulated proteins between benign and tumorous samples of FF and FFPE tissues in a patient cohort. Volcano plots
show proteins with significant abundance difference between tumor and benign tissue in FFPE (A) and FF (B) samples from the PCF
dataset. Proteins showing an abundance difference of fold-change (FC) ≥ 2 and with P value ≤ 0.05 between groups were considered
significant. Boxplots and Kaplan–Meier plots show expression of AGR2 (C) and POSTN (D) in benign and tumorous FF and FFPE samples.
(E) TMAs of FFPE samples matching those analyzed by mass spectrometry were constructed and stained with an antibody against POSTN.
The intensity of stromal POSTN immunoreactivity was scored semiquantitatively by assigning four scores (0, 1+, 2+,3+) to each sample.
Graphs depict examples of stromal staining. Diameter of each tissue core was 0.6 mm. (F) Comparison of POSTN expression as measured
by immunohistochemistry, and the results from PCT-SWATH in FF and FFPE samples. Statistically significant differences between groups
were calculated using two-sided Student t-test. (G) Kaplan–Meier biochemical recurrence-free survival plots of prostatectomy patients
stratified by stromal POSTN immunoreactivity in PCa. (H) POSTN staining of a TMA.
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and FF proteomes and the fact that the FFPE and FF
samples were from different regions of the tumors. In
addition to these three proteins, a further eight pro-
teins were detected at increased abundance in FFPE
tumor compared to benign tissue and thirteen proteins
were detected at lower abundance in the tumor vs.
benign samples (Fig. 4A).
To verify whether the findings from our SWATH
dataset of ProCOC (Umbehr et al., 2008) patients are
consistent with IHC reports, we analyzed a TMA from
18 patients which were also part of the cohort ana-
lyzed by PCT-SWATH. Representative staining images
of POSTN are shown in Fig. 4E. We scored the stain-
ing patterns into four grades (0, 1+, 2+, and 3+) and
compared the results with the SWATH signals of the
corresponding FF and FFPE samples. We analyzed
the statistical significance by pairwise comparison of
groups using Student’s t-test, and single-factor
ANOVA (Fig. 4F, Table S2). We did not observe any
significant difference between the data from FF sam-
ples and from FFPE at the level of the mass spectrom-
etry data. Remarkably, the ANOVA revealed
significant correlation between IHC and both FF and
FFPE SWATH data (Fig. 4F). Taken together, the
IHC results and orthogonal technique confirmed the
similarity of POSTN abundance patterns of POSTN
detected in FFPE and FF samples by mass spectrome-
try. Nevertheless, the difference among the IHC
groups 0, 1+, and 2+ appeared mostly insignificant at
the SWATH level (Fig. 4F). The prognostic role of
POSTN was further confirmed in the survival analysis
based on the TMA data (Fig. 4G). In an independent
Swiss TMA cohort, we also observed significantly
higher abundance of POSTN (P value < 0.001 by
Fisher’s exact test, Fig. 4H) in tumor vs, benign tissue.
We then checked the functions and applications of
the 24 proteins significantly regulated proteins in the
FFPE subcohort based on literature mining. Here, we
discussed some of them which had been studied and
reported extensively. Q7L266 (ASRGL1) was found to
be significantly upregulated in FFPE tumor samples,
whereas the quantitative difference in FF samples was
not significant. The full name of ASRGL1 is isoas-
partyl peptidase/l-asparaginase protein, which is an
enzyme involved in the production of l-aspartate.
ASRGL1 was overexpressed in PCa and regarded as
the potential diagnostic and therapeutic target (Weidle
et al., 2009). Among the 13 downregulated proteins
identified in FFPE cohort, desmin (DES, P17661) is a
known marker protein for prostate smooth muscle
(Shapiro et al., 1992). The decreased abundance of
DES in tumor tissue may reflect the decreasing of
smooth muscle tissue by invasion of malignant cells.
We also found that c-Src tyrosine kinase (CSK,
P41240), a regulator of SRC kinase (Varkaris et al.,
2014), was found to be downregulated in tumor tissue.
With respect to decorin (DCN, P07585), a proteogly-
can in the tumor microenvironment, our data for the
first time report its downregulation in association with
PCa prognosis. This observation is in line with a previ-
ous mouse-based functional study reporting that DCN
specifically inhibits EGFR and AR phosphorylation,
leading to suppressed AR nuclear translocation and
inhibition of PSA production (Hu et al., 2009). While
most protein changes were detected in both tissue
types, the FFPE samples exposed the protein regula-
tion with better statistical power (Fig. 4A). POSTN
was detected to be significantly upregulated in both
FF and FFPE tumor samples in this cohort. CSK and
DCN were only significant in the FFPE cohort, indi-
cating the FFPE proteomes analyzed by our method
are more robust.
Furthermore, by integrating the seven proteins
(POSTN, AGR2, SPON2, ASRGL1, DES, CSK, and
DCN) discussed above, we achieved an AUC of 0.983
for FF samples and 0.977 for FFPE samples, respec-
tively (Fig. S8a) for the separation of tumor and
benign tissue. Our data again demonstrated the consis-
tency of FFPE and FF proteome maps acquired by
the PCT-SWATH workflow and the ability to identify
differentially abundant proteins from either sample
type. Further, the data show that the observed abun-
dance differences were attenuated in FF samples com-
pared to their FFPE counterparts. This could be due
to gradual protein degradation during long-term stor-
age in the frozen state.
3.5. Integrative protein signature for stratifying
PCa
We applied the same workflow as above to another
cohort from China (in the following termed as ‘PCZA’
cohort) to stratify PCa. The PCZA cohort contains
samples from 58 PCa patients and 10 benign prostate
hyperplasia (BPH) patients that have been stored as
FFPE samples for up to 2 years. Three punches for
each sample were analyzed. Of these samples, we ran-
domly selected 33 for technical replicates (Table S3).
Altogether, 237 SWATH files were acquired. To cover
more proteins, we adopted an extended 120 min LC
gradient in a TripleTOF 5600+ coupled to an Eksigent
microflow system. The resulting data were processed
as described above. From 4144 SwissProt proteins
quantified with high degree of reproducibility (Fig. S9)
in this dataset, we identified 241 upregulated proteins
and 89 downregulated proteins (adjusted P value
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cutoff 0.05, FC cutoff 2) (Table S3, Fig. S9). We per-
formed ingenuity pathway analysis (IPA) (Kramer
et al., 2014) of these significantly regulated proteins
between PCa and BPH groups and found that five top
upstream regulator pathways were enriched from these
proteins (Table S4). MYCN, MYC, TCR regulator
pathways were activated while sirolimus and 5-fluo-
rouracil regulator pathways were inhibited (Table S4).
Sixteen cellular networks were enriched from these
proteins via IPA (Table S4).
PCZA and PCF datasets shared seven common regu-
lated proteins in prostate tumor tissues, which are
O14773 (TPP1), O95994 (AGR2), P22626
(HNRNPA2B1), P40926 (MDH2), Q9BUD6 (SPON2),
P17661 (DES), Q7L266 (ASRGL1), as shown in
Fig. S8b. Besides, other significantly regulated proteins,
including P07288 (KLK3), Q00796 (SORD), P21333
(FLNA), P09936 (UCHL1), and Q9UKU7 (ACAD8),
were also identified to show diverse functions by IPA
(Table S4). These proteins were enriched in nine net-
works by IPA, as shown in Fig. S10. The relative abun-
dance of these proteins in both cohorts was calculated,
and the regulation pattern of them in two cohorts was
consistent with each other, as was shown in Fig. 5. The
regulation of these proteins between tumor and benign
tissues was much more significant in PCZA cohort as
was demonstrated by P values. PCZA consists two
groups of 58 PCa patients and 10 BPH patients, while
PCF contains the tumor/benign pair of tissue from 24
PCa patients. Three thousand and thirty proteins were
quantified from PCF cohort by the 30 min LC plus 48-
variable-window scheme from 224 Swath files in Zurich,
while 4144 proteins were quantified in PCZA cohort by
the 120 min LC plus 48-variable-window scheme from
237 Swath files in Hangzhou, both using AB Sciex Tri-
pleTOF 5600+. The two cohorts shared 2846 proteins in
common, accounting for 93.9% of the PCF whole pro-
teome. Then, we calculated the Pearson correlation of
PCF and PCZA FFPE tumor proteomes with the r
value 0.514, reflecting the existence of certain degree of
biological variations between the Swiss and Chinese
cohorts (Fig. S9c). By loosening the threshold for signifi-
cantly regulated proteins in PCF cohort, more proteins
would be distinguished out to be deregulated between
tumor and benign conditions, as was shown in Fig. 5.
KLK3 is the prostate-specific antigen (PSA), a
serum marker for PCa. Sorbitol dehydrogenase
(SORD) converts sorbitol to fructose. SORD is part of
the polyol pathway that plays an important role in
sperm motility. SORD is regulated by androgens in
the human prostate and reported to be positively asso-
ciated with Gleason scoring and serum PSA concentra-
tions (Szabo et al., 2010). Our data show that both
KLK3 and SORD were significantly overexpressed in
PCa tissues. Both Filamin-A (FLNA) and Filamin-B
(FLNB) were proposed as protein panel signatures for
diagnosis of PCa (Narain et al., 2017; Ravipaty et al.,
2017). FLNA was found to be downregulated in PCa
tissues. UCHL1 is a ubiquitin–protein hydrolase
involved in the processing of ubiquitin precursors. Our
data show significant suppression of UCHL1 in tumor
tissues, in agreement with a previous report, further
consolidating its value in PCa biology (Ummanni
et al., 2011). Besides, ACAD8, the acyl-CoA dehydro-
genase family member 8, was detected to be upregu-
lated in tumor tissues in this study. It has been
reported to be a potential prognosis biomarker indicat-
ing the outcome of prostate tumors (Sinha et al.,
2019).
As discussed above, seven common regulated pro-
teins were identified in both PCZA and PCF datasets,
which are TPP1, AGR2, HNRNPA2B1, MDH2,
SPON2, DES, and ASRGL1. Tripeptidyl-peptidase 1
(TPP1) was found to be upregulated. TPP1 is a pri-
mary protector of telomere DNA and has been
reported to be an effective anticancer target for about
90% of human tumors that are telomerase-positive
(Nakashima et al., 2013). Heterogeneous nuclear
ribonucleoproteins (HNRNPs) associate with nascent
pre-mRNAs and package them into HNRNP particles
in a sequence-dependent way. HNRNP particles serve
to condense and stabilize the transcripts and minimize
tangling and knotting. The splicing factor HNRNPA1
has been reported to contribute to enzalutamide resis-
tance by promoting AR-V7 (Tummala et al., 2017). In
this study, HNRNPA2B1 was found to be a novel
upregulated protein probably modulating splicing in
PCa cells. Malate dehydrogenase 2 (MDH2) was also
upregulated in prostate tumor tissues in both PCF and
PCZA cohort in this study. MDH2 is a mitochondrial
enzyme that catalyzes the NAD/NADH-dependent,
reversible oxidation of malate to oxaloacetate. Interest-
ingly, a very recent report on integrative proteomics in
PCa uncovers two metabolic shifts in the citric acid
cycle (TCA cycle) during PCa development and pro-
gression, among which MDH2 is a component.
Increased MDH2 expression in PCa correlated with an
increase in mRNA levels, and it is further upregulated
in CRPC samples (Latonen et al., 2018). Together,
these data suggest that development of MDH2 inhibi-
tion could be of great benefit against progressed PCa.
We further applied the 12-protein panel to both the
Swiss and Chinese PCa cohorts, to evaluate the sensi-
tivity and specificity in diagnosis of PCa. These pro-
teins and their ROC curves using the PCF and PCZA
FFPE datasets are shown in Fig. S8b. They exhibited
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Fig. 5. Relative abundance of the twelve proteins in paired normal and tumor prostate samples in PCF cohort and BPH/tumor samples in
PCZA cohort, respectively. FLNA, UCHL1, and DES were downregulated in tumor tissues, while others were upregulated.
14 Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Unarchiving FFPE tissue proteomes with PCT-SWATH Y. Zhu et al.
high AUC values. Integrative models demonstrated
AUC values of 1 in the FFPE samples of the PCF
cohort. In the independent PCZA cohort, the AUC
reached 0.991. An independent FFPE cohort from a
different country therefore confirmed the diagnostic
significance of these novel proteins in PCa. Taken
together, these findings demonstrate that our pro-
teomic methodology is robust and has the capacity to
uncover new diagnostic protein biomarkers for PCa.
Subsequently, we identified differentially expressed
proteins distinguishing patient groups classified by
Gleason scores. In this study, 24 PCa patients from
the PCF cohort and 58 PCa patients from PCZA
cohort were classified into three groups according to
their tumor grades as reflected by Gleason, namely,
low (L), intermediate (M), and high stage (H)
(Table S5). ANOVA was employed to compare pro-
teomes among three stages to identify protein candi-
dates that distinguish different stages of cancer
progression (P value < 0.05). 216 proteins and 373
proteins were detected significantly regulated in the
PCF cohort and the PCZA cohort, respectively, with
23 proteins overlapping (Table S5). PCA (Fig. S11)
demonstrated clear separation of L and H grades;
however, it was challenging to distinguish M from L
and H grades, consistent with the pathological nature
of the samples, indicating that proteome acquired by
our method well preserved the granularity of the
FFPE tissue samples.
3.6. Prognostic markers for diffuse large B-cell
lymphoma
Having established that the PCT-SWATH method was
applicable to analyze prostate FFPE samples and to
consistently distinguish malignant and benign samples
in two independent sample cohorts, we next asked
whether the method could stratify other types of
tumors based on overall survival. We procured 41
patients with DLBCL (in the following termed as
‘WLYM’ cohort) from the University Hospital Zurich
to investigate prognostic markers. DLBCL is a disease
with relatively poor prognosis and includes different
subtypes, that is, lymphomas residing exclusively in
the brain, known as primary central nervous system
lymphomas (PCNSL) and extracerebral DLBCL
(eDLBCL). Another distinct entity, intravascular lym-
phoma (IVL), is a rare type confined to the lumina of
blood vessels (there is only one IVL patient in WLYM
cohort, Fig. S12). About 70% cases of eDLBCL are
curable; however, the median survival of patients with
PCNSL is only about 30 months in contemporary clin-
ical trials (Korfel et al., 2015).
To identify prognostic proteins for DLBCL, two to
three FFPE punches were analyzed for each of the 41
DLBCL tumors (Table S6, Fig. S12). Altogether, we
acquired 113 SWATH maps using a 60-min LC gradi-
ent, and a TripleTOF 6600 mass spectrometer. We
quantified 5769 SwissProt proteins in all samples
(Table S6, Fig. S13). The technical reproducibility for
a representative sample is shown in Fig. S12d. Ninety-
one proteins were detected to be significantly upregu-
lated, and six proteins were detected to be downregu-
lated in the PCNSL tumors compared to eDLBCL
tumors (Fig. S12e, Table S6). Of these, 20 proteins
were suspected to be contaminants from brain tissue
based on their brain tissue expression annotation in
the DAVID database and the human protein atlas
(Table S6; Uhlen et al., 2015). Seventeen proteins were
further selected from the remaining 77 proteins accord-
ing to their applications in biomarker and drug target
studies as revealed by IPA (Kramer et al., 2014;
Table S6). Their relative abundance of these proteins
in both eDLBCL and PCNSL groups is shown in
Fig. S14.
ROC analyses based on these seventeen proteins in
both eDLBCL and PCNSL patient samples from
WLYM cohort were performed. Two proteins includ-
ing glial fibrillary acidic protein (P14136, GFAP) and
zeta chain of T-cell receptor-associated protein kinase
70 (P43403, ZAP70) exhibited high AUC values
(Fig. 6A) to differentiate eDLBCL and PCNSL sub-
types of DLBCL. GFAP is a class-III intermediate fil-
ament and a cell-specific marker that distinguishes
astrocytes from other glial cells during the develop-
ment of the central nervous system. We found that
GFAP is a novel upregulated marker in PCNSL.
ZAP70 is a tyrosine kinase that is essential for initia-
tion of T-cell antigen receptor signaling. ZAP70 defi-
ciency is associated with Immunodeficiency 48 that is a
form of severe immunodeficiency characterized by a
selective absence of CD8+ T cells (Arpaia et al., 1994).
Here, we found that ZAP70 was upregulated in the
eDLBCL subtype compared with PCNSL, indicating
the role of ZAP70 in immunological processes during
the progress of the disease.
To further investigate the prognostic value of the
proteins identified above, we procured a second cohort
of 52 eDLBCL patients from China (in the following
termed as ‘ZLYM’ cohort) and performed FFPE
PCT-SWATH analysis using a TripleTOF 5600+ cou-
pled to an Eksigent microflow LC system (Table S7).
Two biological replicates were analyzed for each
patient. Here, we quantified 6266 proteotypic Swis-
sProt proteins in 52 microsectioned tissue samples
from these DLBCL patients in technical duplicate.
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Fig. 6. (A) ROC analysis for the diagnostic power of GFAP and ZAP70 to distinguish eDLBCL and PCNSL subtypes in WLYM cohort. (B)
Survival analysis of a six-protein panel for eDLBCL patients in both WLYM and ZLYM cohorts. (C) Representative IHC staining of MPO in
two eDLBCL patients in the Zurich WLYM cohort. The length of the scale bar is 100 lm.
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Sixteen out of 17 proteins identified in the WLYM
cohort described above were also identified in the
ZLYM cohort. Survival analysis of the 16 proteins in
both groups of eDLBCL patients (WLYM and
ZLYM) was further performed through Kaplan–Meier
plot. The result showed that besides ZAP70, five addi-
tional proteins, namely crystallin alpha B (P02511,
CRYAB), Golgi membrane protein 1 (Q8NBJ4,
GOLM1), myeloperoxidase (P05164, MPO), micro-
tubule-associated protein 1A (P78559, MAP1A), and
ubiquitin C-terminal hydrolase L1 (P09936, UCHL1),
were found to show consistent trend in predicting the
survival outcome in both WLYM and ZLYM
eDLBCL patient cohorts, although the P values in
most cases are not very significant due to the small
size of the cohorts that were available for this rare dis-
ease (Fig. 6B). CRYAB has the function of preventing
aggregation of various proteins under a wide range of
stress conditions. GOLM1 is highly expressed in colon,
prostate, trachea, and stomach. Our study identified
them as novel biomarkers for eDLBCL patients.
Myeloperoxidase is a lysosomal protein known as
expressed in azurophilic granules (primary lysosomes)
of normal myelomonocytic cells which is released into
the extracellular space during degranulation. MPO
functions as part of the host defense system of poly-
morphonuclear leukocytes. It is responsible for micro-
bicidal activity against a wide range of organisms.
MPO has been reported to be related to myeloperoxi-
dase deficiency (MPOD) that is characterized by
decreased myeloperoxidase activity in neutrophils and
monocytes that results in disseminated candidiasis
(Kizaki et al., 1994). MAP1 is a structural protein
involved in the filamentous cross-bridging between
microtubules and other skeletal elements. MAP1A/B
are neuron-specific microtubules (Halpain and Deh-
melt, 2006). MAP1S has been reported to interact with
mitochondrion-associated leucine-rich PPR-motif con-
taining protein that interacts with the mitophagy ini-
tiator and Parkinson disease-related protein Parkin
(Xie et al., 2011). UCHL1 gene mutations are involved
in Parkinson disease 5 that is characterized by a com-
plex neurodegenerative disorder with manifestations
ranging from typical Parkinson disease to dementia
with Lewy bodies (Liu et al., 2002). As discussed
above, UCHL1 is also a tumor suppressor in a broad
range of cancers including PCa. eDLBCL patients with
lower expression level of MPO, MAP1, UCHL1, and
ZAP70 were found to have higher survival rate in this
study.
Higher expression of MPO in eDLBCL patients was
associated with worse survival, as was shown in
Kaplan–Meier plot (Fig. 6B). IHC staining of MPO in
DLBCL tumors from two patients in WLYM cohort
confirmed the presence of MPO-positive regions
(Fig. 6C). Detection of increased abundance of MPO
in eDLBCL group compared to the PCNSL group
might indicate the presence of coagulative necrosis
with penetration of MPO+ granulocytes in the aggres-
sive subset of DLBCLs (Song et al., 2017). Taken
together, the data suggest that MPO is a robust prog-
nostic marker for DLBCL patients. This also supports
the robustness of this proteomic methodology, even if
independent sample cohorts are studied in different
laboratories and instruments. The data from punches
from the WLYM cohort matched well with the sec-
tioned samples from the ZLYM cohort.
4. Discussion
Most archived tissues in pathology collections exist as
FFPE samples, representing a rich resource for clinical
research. Over the past decade, MS-based shotgun
proteomics has been used to analyze proteins from
FFPE samples (Broeckx et al., 2016; Fowler et al.,
2014; Fu et al., 2013; Giusti and Lucacchini, 2013;
Gustafsson et al., 2015; Jain et al., 2012; Jiang et al.,
2007; Ostasiewicz et al., 2010; Shen et al., 2015; Wak-
abayashi et al., 2014; Wisniewski et al., 2012). How-
ever, the concern remains that FFPE samples may
harbor greater variation in protein quality than FF
samples due to formalin-induced chemical modifica-
tions (Gaffney et al., 2018). Ostasiewicz et al. (2010)
performed a comparison of FFPE and FF mouse liver
tissues and found similar protein pattern. However,
this was not confirmed in human tissues. Recently, Pie-
howski et al. (2018) analyzed 60 FFPE ovarian cancer
samples with the storage from 7 to 32 years using
TMT 10-plex isobaric labeling method coupled with
shotgun proteomics approach and reported no signifi-
cant proteome expression difference in terms of age
and storage time. This is an informative study investi-
gating the clinical value of FFPE samples; however,
the practicality, robustness, and reproducibility of
FFPE proteomics, in terms of sample preparation and
LC-MS analyses, have not been rigorously established.
Procurement of a suitable cohort sample for rigorous
comparison of FFPE and FF samples is critical for
validating the practicality.
In this study, based on the ProCOC cohort
(Umbehr et al., 2008) which allowed access to prostate
tissue samples from adjacent sections of the same
resected tissue was stored in both FFPE and FF for-
mat with the storage over 4–8 years, we performed rig-
orous proteomic comparison between them. PCT-
SWATH analysis of 224 PCa FFPE and FF samples
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in PCF cohort facilitated a rigorous comparison in a
clinical scenario in this study. Regarding the storage
factors that might affect the whole proteome, compar-
ison of proteome maps of FFPE samples stored for
8 years and for 4 years did not show significant pat-
tern differences (Fig. S7). A further overall investiga-
tion of FFPE sample proteome maps storing from 1
to 15 years in an independent cohort (PCZC) did not
show significant pattern differences either (Fig. 3).
Besides, proteome maps from two types of FFPE tis-
sue forms (sections vs. punches) are generally similar;
however, they could be separated from each other by
PCA (Fig. 3). The detailed information of patient
cohorts and peptide samples is summarized in
Fig. S16.
Since proteins in FFPE tissue are extensively and
substantially modified by formalin (Giusti and Lucac-
chini, 2013; Ramos-Vara and Miller, 2014), one would
not expect complete recovery of the entire proteome,
and quantitatively identical recovery of every peptide
in various samples. Previous studies have investigated
this issue in depth (Deeb et al., 2015; Kennedy et al.,
2016; Zhang et al., 2015). Indeed, we observed a slight
global difference in TIC between comparable FFPE
and FF proteomes (Fig. S2). However, we also show
that these differences do not distort the proteome pat-
terns to a degree that would preclude their use for tis-
sue classification, suggesting that the slight differences
observed between FF and FFPE tissue samples are
smaller or comparable to other preanalytical factors
(Abdullah Al-Dhabi et al., 2016). This observation is
significant because frequently, longitudinal sample col-
lections that are invaluable for biomarker discovery
are stored in FFPE format. Remarkably, despite a
number of potential confounding factors, we success-
fully identified the same protein biomarker candidates
from matching FFPE and FF samples in the ProCOC
cohort, even though the FFPE and FF samples were
actually from different, albeit consistently scored sec-
tions in these prostate samples. To the best of our
knowledge (Broeckx et al., 2016; Fowler et al., 2014;
Fu et al., 2013; Giusti and Lucacchini, 2013; Gustafs-
son et al., 2015; Jain et al., 2012; Jiang et al., 2007;
Ostasiewicz et al., 2010; Shen et al., 2015; Wak-
abayashi et al., 2014; Wisniewski et al., 2012), this is
the first study in which the proteome of FFPE and FF
has been rigorously compared in a clinical scenario.
Regardless of the variable formalin fixation pro-
cesses of tissue specimens, reproducible sample prepa-
ration and LC-MS analysis are essential for clinical
studies. Due to the complexity (dozens to hundreds of
fractions for a single sample) and high cost of the
lengthy shotgun proteomic workflow (hundreds to
thousands of MS analyses for a single cohort), few
published studies on FFPE/FF proteomic analyses
have ever attempted to repeat analysis on clinical spec-
imens of a cohort (Holfeld et al., 2018). A rapid and
robust methodology for quantitatively measuring pro-
teomes of FFPE tissue specimens at low-cost and in a
high-throughput manner is in great need.
In this study, we identified twelve potential protein
biomarker candidates including KLK3, SORD,
AGR2, SPON2, MDH2, ACAD8, TPP1, DES,
HNRNPA2B1, ASRGL1, UCHL1 and FLNA as dif-
ferentially abundant between tumor and benign tissues
from two independent PCa cohorts, PCF and PCZA
(Fig. 5). To evaluate the quantitative PCa proteome
maps generated in this study, as well as to investigate
the biological differences among different PCa cohorts
from different countries, we compared our PCF and
PCZA proteomes with the two representative PCa pro-
teomes generated by Iglesias-Gato et al. (2016) and
Latonen et al. (2018), respectively. Three thousand
and thirty proteins were quantified from PCF cohort,
and 4144 proteins from PCZA cohort in this study.
Iglesias-Gato et al. (2016) used the Super-SILAC
labeling plus multifractionation integrated with shot-
gun MS method, to profile proteotypes of 28 prostate
tumors (Gleason score 6–9) FFPE samples and neigh-
boring nonmalignant FFPE tissue in eight cases (sec-
tions of 10 lm thickness and 25 mm2 area), and
quantified 1216 proteins from over 9000 protein identi-
fications. Latonen et al. reported high-throughput
SWATH-MS proteotyping of fresh clinical tissue sam-
ples (5 lm thickness slices for each sample) of 10 BPH
patients, 17 untreated PCa patients, and 11 CRPC. In
PCa vs BPH, they quantified 3394 proteins, which is
comparable with our results regarding quantified pro-
tein number. Moreover, ACO2 and MDH2, two com-
ponents in TCA cycle during PCa development and
progression, were identified (Latonen et al., 2018). In
our study, the overexpression of MDH2 in PCa tissues
in both PCF and PCZA cohort was characterized,
which was consistent with Latonen’s report. Venn dia-
gram showed that PCF, PCZA, and Latonen cohorts
shared 2277 common proteins in total, representing
67% of the Latonen proteome, as was shown in
Fig. S15 and Table S8. PCF, PCZA, and Iglesias-Gato
cohorts shared 700 proteins in total, representing 57%
of the quantified proteome by Iglesias-Gato. Besides,
in Iglesias-Gato cohort, five proteins from our 12-pro-
tein list were found to be significantly regulated, which
were MDH2, TPP1, UCHL1, FLNA, and ACAD8. In
Latonen cohort, six proteins, MDH2, TPP1, AGR2,
DES, HNRNPA2B1, and ACAD8, were found to be
significantly regulated. Detailed information of protein
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regulation of the twelve protein biomarker candidates
was shown in Table S8. The four cohorts revealed
common proteins biomarkers and showed good consis-
tence although there were biological differences among
patients from different countries. Taken together, the
presented data not only demonstrate the practicality of
using FFPE samples for robust PCa biomarker discov-
ery, more importantly, it also identified a panel of pro-
tein biomarker candidates for PCa diagnosis, among
which MDH2, TPP1, and ACAD8 were most signifi-
cant regardless of tissue formats (fresh or FFPE,
punch or micrometer section) and patient populations.
The overlap of the four proteomes confirmed the tech-
nical reliability, robustness, and transferability of our
FFPE PCT-SWATH pipeline among different studies,
cohorts, and laboratories from another point of view.
The hereinabove studied PCa cohort offers a
rational model to benchmark the similarity of FFPE
and FF proteome due to the availability of both types
of tissue samples from adjacent regions with relatively
high degree of homogeneity. However, PCa patients
generally exhibit positive prognosis after prostatec-
tomy. To further explore the generic applicability of
the method and to explore the feasibility of identifying
prognostic markers in another clinical setting, we ana-
lyzed 113 FFPE samples from a cohort of 41 Swiss
DLBCL patients from Zurich with up to 125-month
follow-up. We further validated the methodology using
the independently established FFPE PCT-SWATH
platform in China and applied it to a second cohort
which comprised 52 Chinese DLBCL patients with up
to 100-month follow-up. Importantly, data from the
two cohorts confirmed MPO as a promising survival
marker (Fig. 6). The discovery of MPO as a potential
prognostic marker for DLBCL is also supported by
the finding that circulating monocytes and neutrophils
are reported to be independent prognostic factor for
DLBCL (Azzaoui et al., 2016). Myeloid cells are pre-
sumably MPO-positive and found to suppress T-cell
responses.
5. Conclusions
In conclusion, we established a workflow for high-
throughput proteomic analysis of large number of
FFPE tissue samples. We demonstrated that FFPE tis-
sue cohorts effectively facilitate biomarker discovery
compared to its FF counterpart via the optimized
FFPE PCT-SWATH proteomics analysis. We also
reported novel promising protein biomarkers for PCa
and DLBCLs. This study indicates that historical
FFPE tissue samples from biobanks have great poten-
tial in biomarker discovery.
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